Growth Drivers
Demographic Advantage
1 million + skilled biotech workforce . Huge knowledge base
Infrastructure
74 bio-incubation centers created through DBT-BIRAC and 4 industry clusters in Kalyani , Pune , Bangalore , Delhi NCR
Government Policies
Critical policy initiatives such as ' Make in India ’, ‘ Startup India ’, ‘ Atmanirbhar Bharat Abhiyan ’ and formulation of the National Biotechnology Development Strategy 2021-25 . Favorable government policies like Draft R & D Policy 2021 , PLI Schemes
Focus on R & D
India has invested U $ 1 billion in biotechnology R & D in 2022 . A trebling within a year from USD 320 million to USD 1.02 billion .
Epidemiological Factors
Increasing population and lifestyle changes . Government expenditure on healthcare up to 2.1 % of GDP in FY21-22 , with a target of 2.5 % of the country ' s GDP by 2025
technological advancement , biopharma players are seeking ways to adopt advanced technologies . “ The companies are incorporating technologies such as robotics , data analytics , different workflows , etc into their processes , as these tools have a great potential to drive innovation and remove inefficiencies and open new avenues to achieve sustainability goals .”
“ Biosolutions are not new to the world . For years , we have depended on the power of bio-solutions to sustain life . Today , the greatest ability of biotechnology is to transform the manufacturing process itself , reducing pollution , conserving natural resources , trimming costs , and expediting new “ greener ” products to market , says Krishna Mohan Puvvada , Regional President , India , Novozymes .
“ The government continues to implement several policies aimed at building momentum in this sector via tax incentives , subsidies , and investment in R & D . However , the critical gaps that needs to be addressed immediately include creating a culture of scientific enquiry from high-school onwards , build world-class facilities to conduct translational research , leveraging the huge patient pool to set up and conduct globally competitive clinical trials . This along with ease of doing business initiatives , ready access to long-term capital and high-end infrastructure , scalability of successful start-ups to take ideas-to-market should enable the development and launch of differentiated products for India and the world ,” says Dr Anand Anandkumar .
Speaking at an event , Dr Rajesh Gokhale , Secretary , DBT , reiterated DBT ’ s commitment to foster enterprise and innovation with new and special emphasis of enhancing manufacturing and biomanufacturing . He added that the process for vaccine preparedness was complex and DBT would facilitate with putting into place easier scientific policy on place .
16
BioVoiceNews | February 2023